| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.
|
J Clin Oncol
|
2002
|
3.75
|
|
2
|
Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel.
|
Ann Oncol
|
2007
|
2.24
|
|
3
|
Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.
|
Ann Oncol
|
2014
|
1.97
|
|
4
|
Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).
|
Br J Cancer
|
2006
|
1.84
|
|
5
|
Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial.
|
Ann Oncol
|
2004
|
1.79
|
|
6
|
High coexpression of both insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth factor receptor (EGFR) is associated with shorter disease-free survival in resected non-small-cell lung cancer patients.
|
Ann Oncol
|
2009
|
1.71
|
|
7
|
A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer.
|
Breast
|
2010
|
1.47
|
|
8
|
Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
|
Ann Oncol
|
2013
|
1.46
|
|
9
|
Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
|
Br J Cancer
|
2007
|
1.33
|
|
10
|
EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab.
|
Ann Oncol
|
2009
|
1.23
|
|
11
|
Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival.
|
Ann Oncol
|
2008
|
1.23
|
|
12
|
Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine.
|
Ann Oncol
|
2010
|
1.14
|
|
13
|
Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations.
|
Cancer Chemother Pharmacol
|
2012
|
1.09
|
|
14
|
Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study.
|
Ann Oncol
|
2009
|
1.02
|
|
15
|
A three-week schedule of gemcitabine-cisplatin in advanced non-small-cell lung cancer with two different cisplatin dose levels: a phase II randomized trial.
|
Ann Oncol
|
2000
|
1.00
|
|
16
|
Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts.
|
Ann Oncol
|
2011
|
0.97
|
|
17
|
Combined cisplatin and gemcitabine for non-small cell lung cancer: influence of scheduling on toxicity and drug delivery.
|
Semin Oncol
|
1998
|
0.95
|
|
18
|
Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian epidemiological study: the NET management study.
|
J Endocrinol Invest
|
2011
|
0.94
|
|
19
|
Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial.
|
Ann Oncol
|
1999
|
0.94
|
|
20
|
Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study.
|
J Cell Mol Med
|
2012
|
0.92
|
|
21
|
Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an Experts Panel Meeting.
|
Crit Rev Oncol Hematol
|
2007
|
0.91
|
|
22
|
Treatment of advanced non-small cell lung cancer.
|
Ann Oncol
|
2006
|
0.91
|
|
23
|
Development of gemcitabine in non-small cell lung cancer: the Italian contribution.
|
Ann Oncol
|
2006
|
0.89
|
|
24
|
Coexistence of EGFR mutation and ALK translocation in NSCLC: literature review and case report of response to gefitinib.
|
Lung Cancer
|
2013
|
0.88
|
|
25
|
Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer.
|
Br J Cancer
|
2004
|
0.88
|
|
26
|
High dose-intensity chemotherapy, with accelerated cyclophosphamide-doxorubicin-etoposide and granulocyte-macrophage colony stimulating factor, in the treatment of small cell lung cancer.
|
Eur J Cancer
|
1993
|
0.87
|
|
27
|
ZD 1839 in patients with brain metastases from non-small-cell lung cancer (NSCLC): report of four cases.
|
Br J Cancer
|
2003
|
0.87
|
|
28
|
Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer.
|
Br J Cancer
|
2005
|
0.86
|
|
29
|
Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma.
|
Br J Cancer
|
2004
|
0.85
|
|
30
|
Cost-minimisation analysis comparing gemcitabine/cisplatin, paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment of advanced non-small cell lung cancer in Italy.
|
Lung Cancer
|
2005
|
0.83
|
|
31
|
Increased levels of circulating DNA in patients with systemic autoimmune diseases: A possible marker of disease activity in Sjögren's syndrome.
|
Lupus
|
2011
|
0.83
|
|
32
|
Gliomatosis cerebri: clinical, neurochemical and neuroradiological response to temozolomide administration.
|
Magn Reson Imaging
|
2003
|
0.81
|
|
33
|
Carboplatin plus pemetrexed for platinum-pretreated, advanced non-small cell lung cancer: a retrospective study with pharmacogenetic evaluation.
|
Cancer Chemother Pharmacol
|
2011
|
0.81
|
|
34
|
Chemotherapy with cisplatin and teniposide for cerebral metastases in non-small cell lung cancer.
|
Lung Cancer
|
1998
|
0.81
|
|
35
|
Concomitant high gene copy number and protein overexpression of IGF1R and EGFR negatively affect disease-free survival of surgically resected non-small-cell-lung cancer patients.
|
Cancer Chemother Pharmacol
|
2013
|
0.80
|
|
36
|
Cyproterone acetate: hepatotoxicity and prostatic cancer treatment.
|
Ann Oncol
|
1993
|
0.79
|
|
37
|
Protein kinase inhibitors in the treatment of renal cell carcinoma: sorafenib.
|
Ann Oncol
|
2007
|
0.79
|
|
38
|
A phase II trial of combined chemotherapy and surgery in stage IIIA non-small cell lung cancer.
|
Lung Cancer
|
1995
|
0.79
|
|
39
|
A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy.
|
Lung Cancer
|
2006
|
0.78
|
|
40
|
Conservative surgery and quality of life in a young patient with synchronous bilateral embryonal carcinoma.
|
Eur Urol
|
1996
|
0.78
|
|
41
|
Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC).
|
Br J Cancer
|
2004
|
0.78
|
|
42
|
Induction chemotherapy with gemcitabine and cisplatin in stage III non-small cell lung cancer.
|
Lung Cancer
|
2001
|
0.78
|
|
43
|
Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer.
|
Br J Cancer
|
2004
|
0.78
|
|
44
|
Lapatinib concentration in cerebrospinal fluid in two patients with HER2-positive metastatic breast cancer and brain metastases.
|
Ann Oncol
|
2014
|
0.77
|
|
45
|
Phase III study in stage IV non-small-cell lung cancer patients treated with two courses of cisplatin/gemcitabine followed by a randomization to three additional courses of the same combination or gemcitabine alone.
|
Ann Oncol
|
2007
|
0.76
|
|
46
|
[Role of irinotecan in the treatment of small cell carcinoma].
|
Tumori
|
2002
|
0.75
|
|
47
|
[Surgery after neo-adjuvant therapy of non-small cell lung cancer. Preliminary results].
|
Minerva Chir
|
1991
|
0.75
|
|
48
|
[Combined chemotherapeutic and radiotherapeutic treatment of limited pulmonary microcytoma].
|
Radiol Med
|
1987
|
0.75
|
|
49
|
Chemotherapy of non-small cell lung cancer.
|
Monaldi Arch Chest Dis
|
1997
|
0.75
|
|
50
|
Neoadjuvant cisplatin and etoposide for stage IIIA (clinical N2) non-small cell lung cancer.
|
Am J Clin Oncol
|
1994
|
0.75
|
|
51
|
Increased bone pain after suspension of buserelin treatment in disseminated prostatic cancer.
|
Lancet
|
1988
|
0.75
|
|
52
|
67Ga scanning in the staging of Hodgkin's disease.
|
Acta Haematol
|
1974
|
0.75
|
|
53
|
Postoperative chemotherapy in non-small cell lung cancer.
|
Tumori
|
2001
|
0.75
|
|
54
|
Cisplatin, etoposide, and mitomycin in the treatment of non-small cell carcinoma of the lung. A pilot study.
|
Cancer
|
1986
|
0.75
|
|
55
|
Reliability and validity of a quality of life questionnaire in cancer patients.
|
Eur J Cancer
|
1993
|
0.75
|
|
56
|
Combination therapy with gemcitabine in non-small cell lung cancer.
|
Eur J Cancer
|
1997
|
0.75
|
|
57
|
Bolus versus 5-day continuous infusion of cisplatin with mitomycin and vindesine in the treatment of advanced non-small cell lung cancer (NSCLC): a phase III prospective randomised trial of the Italian Oncology Group for Clinical Research (GOIRC).
|
Eur J Cancer
|
1998
|
0.75
|
|
58
|
Acute myeloblastic leukemia after adjuvant chemotherapy with melphalan in breast cancer. Case report with cytogenetic analysis.
|
Tumori
|
1983
|
0.75
|
|
59
|
[Medical treatment of pulmonary neoplasms].
|
Recenti Prog Med
|
2001
|
0.75
|